Confluence Life Sciences

Confluence Life Sciences is a biotechnology firm specializing in the discovery and early development of kinase inhibitors to treat cancer and inflammatory and immunological disorders. The company was founded in 2010 in St. Louis, Missouri, by a group of former Pfizer executives, including lead founder Joseph Monahan, who became the Chief Scientific Officer, and Walter Smith, who served as CEO. This initiative followed Pfizer's downsizing of its St. Louis operations, with the founding team leveraging their extensive experience in drug discovery to form the new enterprise.

The company's business model operated on two parallel tracks: developing its own pipeline of proprietary drug candidates and providing contract research services through its subsidiary, Confluence Discovery Technologies. This contract research organization (CRO) served a range of clients from large pharmaceutical corporations to smaller biotech startups, generating revenue that helped fund the company's internal research and development efforts. The company's core scientific focus was its KINect™ platform, a technology designed to accelerate the identification of drug candidates that target specific protein kinases, which are crucial in regulating cellular pathways involved in disease. Key programs in its internal pipeline included CDD-450, a novel MK-2 pathway inhibitor, as well as soft JAK and ITK inhibitor programs aimed at various autoimmune and inflammatory conditions.

In August 2017, Confluence Life Sciences was acquired by Aclaris Therapeutics, a biopharmaceutical company focused on dermatology. The acquisition was valued at up to $100 million, including an upfront payment of $20 million in cash and stock, with an additional $80 million in potential milestone payments and future royalties. The deal allowed Aclaris to absorb Confluence's research team and its pipeline of kinase inhibitors, expanding its focus into new therapeutic areas. Aclaris retained Confluence's operations and scientific team in St. Louis, integrating it as a key research and discovery division.

Keywords: kinase inhibitors, drug discovery, autoimmune diseases, contract research organization, oncology, inflammation, immunological disorders, Aclaris Therapeutics, Joseph Monahan, KINect platform, small molecule drugs, biopharmaceutical, Pfizer, drug development, preclinical research, cancer immunotherapy, dermatology, CDD-450, JAK inhibitors, ITK inhibitors